4.7 Article

Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022

Journal

EUROPEAN JOURNAL OF CANCER
Volume 180, Issue -, Pages 158-179

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2022.11.008

Keywords

Soft tissue sarcoma; Diagnosis; Imaging; Peri-operative management; Treatment of advanced disease; Multimodal treatment; Surveillance; Policy; Consensus

Categories

Ask authors/readers for more resources

This article summarizes the multiple issues and controversies in the diagnosis, treatment, and follow-up of soft tissue sarcoma (STS). It also identifies scientific questions that need to be addressed for improved patient management and outcomes. The study used a modified Delphi process and a voting survey to gather experts' opinions and determine areas of consensus and controversy. The article proposes future scientific questions, clinical trials, quality assurance, and actions by stakeholders to enhance the management and research in STS.
Background: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence. Methods: During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma. We conducted a vote on STS key questions and controversies prior to the CSSS meeting, which took place in May 2022. Results: Sixty-two European sarcoma experts participated in the survey. Sixteen strong consensus (>95%) items were identified by the experts, as well as 30 items with a >75% consensus on diagnostic and therapeutic questions. Ultimately, many controversy topics remained without consensus. Conclusions: In this manuscript, we summarise the voting results and the discussion during the CSSS meeting. Future scientific questions, priorities for clinical trials, registries, quality assurance, and action by stakeholders are proposed. Platforms and partnerships can support innovative approaches to improve management and clinical research in STS. 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available